Boundless Bio (BOLD)

• Market cap: $29.1M
• 1 day: -5.11%
• 5 days: -10.96%
• 1 month: 4.84%
• 3 months: 8.33%
• 6 months: -17.2%
• Year to date: -52.38%
• 1 year: -55.33%
• 5 years: -90.88%
• 10 years: -90.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 64